Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.

Clarke DK, Nasar F, Chong S, Johnson JE, Coleman JW, Lee M, Witko SE, Kotash CS, Abdullah R, Megati S, Luckay A, Nowak B, Lackner A, Price RE, Little P, Kalyan N, Randolf V, Javadian A, Zamb TJ, Parks CL, Egan MA, Eldridge J, Hendry M, Udem SA.

J Virol. 2014 Jun;88(12):6690-701. doi: 10.1128/JVI.03441-13. Epub 2014 Apr 2.

2.

Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.

Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, Johnson JE, Coleman JW, Lee M, Kotash C, Yurgelonis I, Natuk RJ, Hendry RM, Udem SA, Clarke DK.

J Virol. 2008 Jan;82(1):207-19. Epub 2007 Oct 17.

3.

Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.

Clarke DK, Cooper D, Egan MA, Hendry RM, Parks CL, Udem SA.

Springer Semin Immunopathol. 2006 Nov;28(3):239-53. Epub 2006 Sep 15. Review.

PMID:
16977404
4.

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, Schadeck EB, Johnson JE, Masood A, Piacente P, Druilhet RE, Barras PW, Hasselschwert DL, Reilly P, Mishkin EM, Montefiori DC, Lewis MG, Clarke DK, Hendry RM, Marx PA, Eldridge JH, Udem SA, Israel ZR, Rose JK.

AIDS Res Hum Retroviruses. 2004 Sep;20(9):989-1004.

PMID:
15585086
5.

Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group.

Vaccine. 2016 Dec 12;34(51):6597-6609. doi: 10.1016/j.vaccine.2016.06.071. Epub 2016 Jul 6. Review.

6.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

7.
8.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
9.
10.

Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.

Virnik K, Hockenbury M, Ni Y, Beren J, Pavlakis GN, Felber BK, Berkower I.

Retrovirology. 2013 Sep 16;10:99. doi: 10.1186/1742-4690-10-99.

11.

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.

Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, Gill K, Verma M, Yu T, Johnson B, Li B, Derdeyn CA, Ibegbu C, Altman JD, Hunter E, Feinberg MB.

J Virol. 2012 Dec;86(23):12605-15. doi: 10.1128/JVI.00246-12. Epub 2012 Sep 12.

12.

A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.

Amara RR, Patel K, Niedziela G, Nigam P, Sharma S, Staprans SI, Montefiori DC, Chenareddi L, Herndon JG, Robinson HL, McClure HM, Novembre FJ.

J Virol. 2005 Dec;79(24):15356-67.

13.

Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions.

Virnik K, Ni Y, Berkower I.

Vaccine. 2013 Apr 19;31(17):2119-25. doi: 10.1016/j.vaccine.2013.02.055. Epub 2013 Mar 6.

PMID:
23474312
14.

Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.

Chin'ombe N.

Viruses. 2013 Aug 28;5(9):2062-78. doi: 10.3390/v5092062. Review.

15.

Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Chege GK, Burgers WA, Stutz H, Meyers AE, Chapman R, Kiravu A, Bunjun R, Shephard EG, Jacobs WR Jr, Rybicki EP, Williamson AL.

J Virol. 2013 May;87(9):5151-60. doi: 10.1128/JVI.03178-12. Epub 2013 Feb 28.

16.

Development of replication-competent viral vectors for HIV vaccine delivery.

Parks CL, Picker LJ, King CR.

Curr Opin HIV AIDS. 2013 Sep;8(5):402-11. doi: 10.1097/COH.0b013e328363d389. Review.

17.

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, Zur Megede J, Polo J, Donnelly J, Ulmer J, Otten GR, Miller CJ, Vajdy M, Srivastava IK.

J Virol. 2010 Jun;84(12):5975-85. doi: 10.1128/JVI.02533-09. Epub 2010 Apr 14.

18.

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus.

Egan MA, Chong SY, Megati S, Montefiori DC, Rose NF, Boyer JD, Sidhu MK, Quiroz J, Rosati M, Schadeck EB, Pavlakis GN, Weiner DB, Rose JK, Israel ZR, Udem SA, Eldridge JH.

AIDS Res Hum Retroviruses. 2005 Jul;21(7):629-43.

PMID:
16060834
20.

Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Braxton CL, Puckett SH, Mizel SB, Lyles DS.

J Virol. 2010 Apr;84(7):3552-61. doi: 10.1128/JVI.01572-09. Epub 2010 Jan 20.

Supplemental Content

Support Center